Purple Book product · Reference 351(a)
Dupixent
dupilumab
Jun 18, 2020
Approved
Reference 351(a)
License type
Rx
Marketing
None
Listed patents
Sourced from the FDA Purple Book · verified Jul 02, 2026
Key dates
Approval
Approval date of this BLA submission.
Jun 18, 2020
6 yr 2 mo ago
Today
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
Jan 25, 2031
in 4 yr 7 mo
Pharmaceutical detail
Strength
300MG/2ML
Dosage form
Injection
Route
Subcutaneous
Presentation
Autoinjector
Center
CDER
License number
1760
Product number
004
Submission type
Supplement
Supplement number
17
Change type
Not listed
Reference product family
View full familyThis is the reference (originator) product. No biosimilars or interchangeables reference it in the Purple Book yet.
5 additional BLA records for this product (other strengths or presentations) are in the same reference family.
Patent list
No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.
Source provenance
- advanced-searchAdvanced Search · Jul 02, 2026
- monthly-downloadMonthly download · Jul 02, 2026
Change history
- v4Jul 02, 2026
- v3Jul 02, 2026
- v2Jul 02, 2026
Frequently asked questions
Does Dupixent have approved biosimilars?
No 351(k) biosimilars or interchangeable biosimilars referencing Dupixent are listed in the FDA Purple Book yet.
What is Dupixent's BLA number?
Dupixent is licensed under BLA 761055, held by Regeneron Pharmaceuticals, Inc..
When was Dupixent approved by the FDA?
Dupixent was approved by the FDA on Jun 18, 2020.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
